ATE188219T1 - Pharmazeutische dipeptid zusammensetzungen und verwendungsmethoden. - Google Patents

Pharmazeutische dipeptid zusammensetzungen und verwendungsmethoden.

Info

Publication number
ATE188219T1
ATE188219T1 AT92922891T AT92922891T ATE188219T1 AT E188219 T1 ATE188219 T1 AT E188219T1 AT 92922891 T AT92922891 T AT 92922891T AT 92922891 T AT92922891 T AT 92922891T AT E188219 T1 ATE188219 T1 AT E188219T1
Authority
AT
Austria
Prior art keywords
methods
trp
glu
formula
pharmaceutically acceptable
Prior art date
Application number
AT92922891T
Other languages
English (en)
Inventor
Vladimir Khatskelevi Khavinson
Vyacheslav Grigorievic Morozov
Sergey Vladimirovich Sery
Original Assignee
Cytran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytran Ltd filed Critical Cytran Ltd
Application granted granted Critical
Publication of ATE188219T1 publication Critical patent/ATE188219T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT92922891T 1991-10-28 1992-10-21 Pharmazeutische dipeptid zusammensetzungen und verwendungsmethoden. ATE188219T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78351891A 1991-10-28 1991-10-28
PCT/US1992/009114 WO1993008815A1 (en) 1991-10-28 1992-10-21 Pharmaceutical dipeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE188219T1 true ATE188219T1 (de) 2000-01-15

Family

ID=25129525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922891T ATE188219T1 (de) 1991-10-28 1992-10-21 Pharmazeutische dipeptid zusammensetzungen und verwendungsmethoden.

Country Status (6)

Country Link
EP (1) EP0614369B1 (de)
JP (1) JPH07503456A (de)
AT (1) ATE188219T1 (de)
AU (1) AU2905092A (de)
DE (1) DE69230500D1 (de)
WO (1) WO1993008815A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5811399A (en) * 1988-12-14 1998-09-22 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
AU7392294A (en) * 1993-07-21 1995-02-20 Vladimir Khatskelevich Khavinson Pharmaceutical with immunomodulating activity
GB9421180D0 (en) * 1994-10-20 1994-12-07 Peptide Therapeutics Ltd Immunomodulatory Polypeptides
RU2107691C1 (ru) * 1995-03-02 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US6103699A (en) 1996-06-07 2000-08-15 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US6159940A (en) * 1996-02-28 2000-12-12 Immunotech Developments Inc. Method for modulating hemopoiesis
US6060452A (en) * 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
AU3467099A (en) * 1998-04-03 1999-10-25 Cytran Ltd. Methods for production of therapeutic cytokines
CN100553636C (zh) 2000-08-04 2009-10-28 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
FR2826278B1 (fr) * 2001-06-20 2005-03-25 Lipha Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
EP1397124B1 (de) * 2001-06-20 2006-11-29 Merck Sante Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels
RU2213571C2 (ru) * 2001-11-30 2003-10-10 Филиппова Ольга Всеволодовна Антигипоксическое средство
WO2004030522A2 (en) 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
EP2517718B1 (de) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Behandlung von T-Zell-vermittelten Krankheiten
EP1840133A1 (de) 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. Neue immunomodulierende Oligopeptide
EA018548B1 (ru) 2006-08-04 2013-08-30 Манус Фармасьютикалз (Канада) Лтд. Полифункциональные биологически активные соединения
KR20090119897A (ko) 2007-02-13 2009-11-20 사이클론 파아머슈티컬 인코오퍼레이티드 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP2613786A4 (de) 2010-09-07 2013-10-23 Dmi Acquisition Corp Behandlung von erkrankungen
EA028343B1 (ru) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Лечение дегенеративного заболевания сустава
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP2771007B1 (de) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Behandlung von rhinitis
DK2827907T3 (da) * 2012-03-20 2019-06-11 Helix Biomedix Inc Korte antimikrobielle lipopeptider
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
RU2540496C1 (ru) * 2014-01-20 2015-02-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Композиция для назального применения, лекарственное средство на его основе и способ его пременения
RU2736513C2 (ru) 2014-08-18 2020-11-17 Ампио Фармасьютикалз, Инк. Лечение патологических состояний суставов
EP3310375A4 (de) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Verwendung von niedermolekularen fraktionen von humanem serumalbumin bei der behandlung von erkrankungen
JP6719475B2 (ja) * 2015-09-04 2020-07-08 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752602A (en) * 1985-09-09 1988-06-21 Board Of Regents, The University Of Texas System Dipeptide alkyl esters and their uses
AU616236B2 (en) * 1987-12-30 1991-10-24 Cytran Ltd. Pharmaceutical preparation for treating immunodeficiency conditions
AU668088B2 (en) * 1991-04-01 1996-04-26 Cytran Ltd. Pharmaceutical dipeptide compositions and methods of use thereof

Also Published As

Publication number Publication date
DE69230500D1 (de) 2000-02-03
WO1993008815A1 (en) 1993-05-13
EP0614369A4 (de) 1994-12-07
JPH07503456A (ja) 1995-04-13
EP0614369A1 (de) 1994-09-14
EP0614369B1 (de) 1999-12-29
AU2905092A (en) 1993-06-07

Similar Documents

Publication Publication Date Title
ATE188219T1 (de) Pharmazeutische dipeptid zusammensetzungen und verwendungsmethoden.
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
DE69228106D1 (de) HIV-Protease-Inhibitoren
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
BG101118A (en) Therapeutical compounds
MXPA02007931A (es) Analogos de nucleosido con base monociclica modificada con carboxamidina.
GR3026218T3 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE156019T1 (de) Lipophile zusammensetzungen von oligosaccharid- antibiotikasalzen
ATE173627T1 (de) Medizinische zusammensetzung
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
RU95110110A (ru) Производные бензофурана, способ их получения, фармкомпозиция и способ лечения
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
ATE260672T1 (de) Pharmazeutische lysin enthaltende polypeptid- zusammensetzungen und verfahren zu deren verwendung
EP0621789A4 (en) Pharmaceutical pentapeptide compositions and methods of use thereof.
RU94046312A (ru) Применение биологически активных уреидопроизводных для лечения индуцируемых лентивирусами заболеваний, продукты, содержащие уреидопроизводные
NO901231L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
JO1664B1 (en) The compound has the effect of immobilizing gastric acid and the process of preparing it
MX9707673A (es) Derivados de ureido biologicamente activos, eficaces en el tratamiento de la esclerosis multiple.
SE8903117D0 (sv) Laekemedel omfattande antamanid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties